Search research articles
Contact Us
Filters
Showing results (61-70 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
Melissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Hemasphere
|
April 20, 2022
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
Martin Dreyling, Andre Goy, Georg Hess, et al.
British Journal of Clinical Pharmacology
|
April 27, 2016
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao, Robert Chen, Owen A O'Connor, et al.
American Journal of Hematology
|
October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
Alex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Investigational New Drugs
|
June 15, 2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K Gopal, Stefano R Tarantolo, Naresh Bellam, et al.
Journal of Hematology & Oncology
|
August 31, 2013
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
Rajendra Gharbaran, Andre Goy, Takemi Tanaka, et al.
Cancer
|
July 23, 2003
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Anas Younes, Jorge Romaguera, Frederick Hagemeister, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
June 17, 2003
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations
Andre Goy, Latha Ramdas, Yvonne K Remache, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 6, 2014
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation
Michele L Donato, David S Siegel, David H Vesole, et al.
British Journal of Haematology
|
August 3, 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
John Gerecitano, Andre Goy, John Wright, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma
Melissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Hemasphere
|
April 20, 2022
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up
Martin Dreyling, Andre Goy, Georg Hess, et al.
British Journal of Clinical Pharmacology
|
April 27, 2016
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao, Robert Chen, Owen A O'Connor, et al.
American Journal of Hematology
|
October 18, 2019
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
Alex F Herrera, Andre Goy, Amitkumar Mehta, et al.
Investigational New Drugs
|
June 15, 2014
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K Gopal, Stefano R Tarantolo, Naresh Bellam, et al.
Journal of Hematology & Oncology
|
August 31, 2013
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
Rajendra Gharbaran, Andre Goy, Takemi Tanaka, et al.
Cancer
|
July 23, 2003
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
Anas Younes, Jorge Romaguera, Frederick Hagemeister, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
June 17, 2003
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations
Andre Goy, Latha Ramdas, Yvonne K Remache, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 6, 2014
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation
Michele L Donato, David S Siegel, David H Vesole, et al.
British Journal of Haematology
|
August 3, 2006
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
John Gerecitano, Andre Goy, John Wright, et al.
Page
of 17